Pfizer IPO, Cost Cuts Yield Time to Reinvent Its Research

Pfizer Inc., the world’s largest drugmaker, put in place the last piece of its plan to refocus the company on developing new drugs, announcing it would start the separation of its animal-health business this month.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.